Long Xingru, Cheng Sixuan, Lan Xiaoli, Wei Weijun, Jiang Dawei
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave., Wuhan, Hubei, 430022, China.
Hubei Key Laboratory of Molecular Imaging, 1277 Jiefang Ave., Wuhan, Hubei, 430022, China.
Eur J Nucl Med Mol Imaging. 2025 May;52(6):2225-2238. doi: 10.1007/s00259-025-07077-6. Epub 2025 Jan 13.
As the smallest antibody fragment with specific binding affinity, nanobody-based nuclear medicine has demonstrated significant potential to revolutionize the field of precision medicine, supported by burgeoning preclinical investigations and accumulating clinical evidence. However, the visualization of nanobodies has also exposed their suboptimal biodistribution patterns, which has spurred collaborative efforts to refine their pharmacokinetic and pharmacodynamic profiles for improved therapeutic efficacy. In this review, we present clinical results that exemplify the benefits of nanobody-based molecular imaging in cancer diagnosis. Moreover, we emphasize the indispensable role of molecular imaging as a tool for evaluating and optimizing nanobodies, thereby expanding their therapeutic potential in cancer treatment in the foreseeable future.
作为具有特异性结合亲和力的最小抗体片段，基于纳米抗体的核医学在新兴的临床前研究和不断积累的临床证据支持下，已显示出变革精准医学领域的巨大潜力。然而，纳米抗体的显像也暴露了其生物分布模式欠佳的问题，这促使各方共同努力优化其药代动力学和药效学特征，以提高治疗效果。在本综述中，我们展示了临床结果，例证了基于纳米抗体的分子成像在癌症诊断中的益处。此外，我们强调分子成像作为评估和优化纳米抗体的工具所发挥的不可或缺的作用，从而在可预见的未来扩大其在癌症治疗中的治疗潜力。
